Focus Equities

Eleven Biotherapeutics Shares Gain

images (11)

Eleven Biotherapeutics shares rose 10% in early trading Thursday after the company said the independent Data and Safety Monitoring Board for a phase 3 trial of Vicinium in non-muscle invasive bladder cancer recommended that the study continues, based on a review of safety and efficacy data.

The trial’s primary endpoint is the complete response rate in patients with carcinoma-in-situ and secondary endpoints include time to disease recurrence and event free survival. The company said the trial has exceeded 50% enrollment so far. Eleven Biotherapeutics said it expects to complete patient enrollment in the second half of 2017 and to report 3-month data in Q2 of 2018.